Dyadic International – DYAI-100

Candidate: DYAI-100 Category: VAX Type: SARS-CoV-2-S-RBD vaccine candidate produced via Dyadic’s C1 technology platform 2021 Status: Dyadic said March 18 that it will begin a toxicology study of DYAI-100 in the second quarter, then advance the vaccine candidate into a first-in-humans Phase I trial in the second half of this year. The plans for the […]

The post Dyadic International – DYAI-100 appeared first on GEN – Genetic Engineering and Biotechnology News.

Published on Wed, 24 Mar 2021 19:35:16 +0000 and brought to you by Apptigent PowerTools